Phenyl Linked Quinolinyl Modulators Of Ror-Gamma-T

A phenyl and methyl technology, applied in anti-inflammatory agents, non-central analgesics, medical preparations containing active ingredients, etc., can solve the problems of EAE sensitivity reduction and Th17 cell population reduction

Inactive Publication Date: 2016-08-03
JANSSEN PHARMA NV
4 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

RORt-deficient mice were apparently healthy and reproduced normally, but displayed impaired Th17 cell differentiation in vitro, significantly reduced numbers of Th17 cell populations in vivo, and...
View more

Method used

[0847] Experiments were performed using equipment owned by Janssen Research and Discovery, L.L.C., which acquired 3-Dimensional Pharmaceuticals, Inc. 1,8-ANS (Invitrogen) was used as fluorescent d...
View more

Abstract

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR[gamma]t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

Application Domain

Organic active ingredientsNervous disorder +9

Technology Topic

PsoriasisUrology +3

Image

  • Phenyl Linked Quinolinyl Modulators Of Ror-Gamma-T
  • Phenyl Linked Quinolinyl Modulators Of Ror-Gamma-T
  • Phenyl Linked Quinolinyl Modulators Of Ror-Gamma-T

Examples

  • Experimental program(97)
  • Effect test(1)

Example Embodiment

[0545] Example 1a: 1-(4-((4-Chloro-2-methoxy-3-(3-(trifluoromethyl)phenyl)quinolin-6-yl)(hydroxy)(1- Methyl-1H-imidazol-5-yl)methyl)piperidin-1-yl)ethanone
[0546]
[0547] At -78°C, add n-butyllithium (1.6M hexane solution, 0.585mL, 0.937mmol) to 6-bromo-4-chloro-2-methoxy-3-(3-(tri Fluoromethyl)phenyl)quinoline (409.8 mg, 0.984 mmol, Intermediate 5: Step e) in THF (3 mL). After 1 minute, 1-(4-(1-methyl-1H-imidazole-5-carbonyl)piperidin-1-yl)ethanone (231.4 mg, 0.984 mmol, Intermediate 1: step c) was added via a cannula THF (5mL) solution. The mixture was stirred at -78°C for 10 minutes, then transferred to an ice bath and stirred for another 45 minutes. Add saturated NH 4 The reaction mixture was quenched with aqueous Cl, diluted with water and extracted with EtOAc (3x). Dry (Na 2 SO 4 ) Organic phase, filtered and concentrated to dryness. The residue was purified by flash column chromatography (silica gel, 0-8% MeOH-DCM) to obtain the target compound as a white solid. MSm/e573.3[M+H] +.
[0548] Purification of 1-(4-((4-chloro-2-methoxy-3-(3-(trifluoromethyl)phenyl)quinolin-6-yl) by chiral HPLC (ChiralcelOD-H, EtOH) (Hydroxy)(1-methyl-1H-imidazol-5-yl)methyl)piperidin-1-yl)ethanone, two enantiomers are obtained. Example 1b: (The first enantiomer eluted from the chiral column) 1 HNMR(400MHz, CDCl 3 , A 1.2:1 mixture of rotamers, the minor rotamer peaks are marked with *)δ8.21(s,1H), 8.16*(br.s.,1H), 7.85*(d,J= 2.53Hz,1H),7.83(d,J=2.53Hz,1H),7.72*(s,1H),7.70(s,1H),7.59-7.66(m,4H),7.54-7.58(m,2H) ,7.41-7.51(m,2H),7.34(s,2H),7.23(s,2H),4.78(d,J=12.63Hz,1H), 4.61*(d,J=12.63Hz,1H),4.01 (s,6H),3.95(d,J=13.14Hz,1H), 3.76*(d,J=11.12Hz,1H), 3.28(s,3H), 3.27*(s,3H),3.11-3.24* (m,1H),2.94-3.04(m,1H),2.56-2.70(m,3H),2.40-2.56(m,3H),2.25-2.38(m,2H),2.05(s,3H)*, 2.03(s,3H),1.13-1.44(m,6H); MSm/e573.2[M+H] + , And Example 1c: (the second enantiomer eluted from the chiral column) 1 HNMR(400MHz, CDCl 3 , A 1.2:1 mixture of rotamers, the minor rotamer peaks are marked with *)δ8.21(s,1H), 8.16*(br.s.,1H),7.84*(d,J= 3.03Hz,1H),7.82(d,J=2.53Hz,1H),7.71*(s,1H),7.69(s,1H),7.58-7.65(m,4H),7.52-7.58(m,2H) ,7.40-7.51(m,2H),7.29-7.35(m,2H),7.22(s,2H),4.77(d,J=13.1Hz,1H), 4.60(d,J=13.6Hz,1H), 4.00(s,6H),3.93(d,J=12.63Hz,1H), 3.74*(d,J=13.14Hz,1H), 3.27(s,3H), 3.26*(s,3H), 3.12-3.22 (m,1H),2.92-3.05(m,1H),2.80(s,1H),2.57-2.74(m,2H),2.39-2.55(m,3H),2.22-2.39(m,2H),2.04 *(s,3H),2.02(s,3H),1.12–1.46(m,6H); MSm/e573.2[M+H] +.

Example Embodiment

[0664] Through saturated NaHCO 3 Partitioning between aqueous solution and DCM neutralizes the racemate. Dry (Na 2 SO 4 ) The organic layer was filtered, concentrated to dryness, and purified by chiral HPLC (ChiralcelOD, 100% EtOH) to obtain two pure enantiomers. Example 34b: (The first enantiomer eluted from the chiral column) 1 HNMR(400MHz, CDCl 3 , About 1.5:1 mixture of rotamers) δ8.45 (d, J = 13.64 Hz, 1H), 8.20 (dd, J = 4.04, 8.59 Hz, 1H), 7.68 (t, J = 10.11 Hz, 1H) ),7.48-7.53(m,3H),7.24-7.34(m,2H),7.10-7.24(m,2H), 4.65(d,J=12.63Hz,0.6H),4.56(d,J=13.14Hz ,0.4H), 3.91(d,J=13.14Hz,0.4H),3.66-3.79(m,0.6H),3.31(s,1.8H), 3.29(s,1.2H), 3.18(t,J= 12.38Hz, 0.4H), 2.97 (t, J = 12.13 Hz, 0.6H), 2.38-2.69 (m, 2H), 2.34 (d, J = 13.14 Hz, 0.4H), 2.22 (d, J = 12.63 Hz ,0.6H),2.01(s,1.8H),1.95(s,1.2H),1.13-1.55(m,2.4H),1.09(d,J=12.63Hz,0.6H); MSm/e543.2[ M+H] +. Example 34c: (the second enantiomer eluted from the chiral column) 1 HNMR(400MHz, CDCl 3 , About 1.5:1 mixture of rotamers) δ8.46 (d, J = 12.63 Hz, 1H), 8.20 (dd, J = 3.79, 8.84 Hz, 1H), 7.68 (t, J = 10.11 Hz, 1H) ),7.46-7.53(m,3H),7.24-7.35(m,2H),7.10-7.23(m,2H), 4.64(d,J=13.14Hz,0.6H),4.55(d,J=12.63Hz ,0.4H), 3.90(d,J=13.14Hz,0.4H), 3.72(d,J=13.14Hz,0.6H), 3.31(s,1.8H), 3.29(s,1.2H), 3.18(t ,J=12.38Hz,0.4H),2.97(t,J=12.38Hz,0.6H),2.38-2.68(m,2H),2.34(d,J=12.63Hz,0.4H),2.21(d,J =13.14Hz,0.6H),2.01(s,1.8H),1.94(s,1.2H),1.12-1.58(m,2.4H),1.08(d,J=12.63Hz,0.6H); MSm/e543 .2[M+H] +.

Example Embodiment

[0549] Example 2a: 6-((1-Acetylpiperidin-4-yl)(hydroxy)(1-methyl-1H-imidazol-5-yl)methyl)-2-methyl Oxy-3-(3-(trifluoromethyl)phenyl)quinoline-4-carbonitrile
[0550]
[0551] Fill a round-bottom flask with 1-(4-((4-chloro-2-methoxy-3-(3-(trifluoromethyl)phenyl)quinolin-6-yl)(hydroxy)(1 -Methyl-1H-imidazol-5-yl)methyl)piperidin-1-yl)ethanone (158mg, 0.276mmol, Example 1a), Zn(CN) 2 (58.3mg, 0.496mmol), Pd 2 (dba) 3 (37.9mg, 0.041mmol), nano zinc powder (5.4mg, 0.083mmol) and dicyclohexyl (2',4',6'-triisopropyl-[1,1'-diphenyl]-2- Yl)phosphine (X-Phos, 27.1 mg, 0.055 mmol). The flask was evacuated and filled with argon (three cycles). Then dimethylacetamide (1.4 mL, filled with argon for 30 minutes) was added, and the mixture was heated at 120°C for 4 hours. The mixture was cooled to room temperature and filtered Wash with EtOAc. Use 2MNH sequentially 4 The filtrate was washed with OH aqueous solution, water and saturated NaCl aqueous solution. Dry (Na 2 SO 4 ) Organic phase, filtered and concentrated to dryness. The residue was purified by flash column chromatography (silica gel, 1-8% MeOH-DCM) to obtain the title compound. MSm/e564.3[M+H] +.
[0552] Purification of 6-((1-acetylpiperidin-4-yl)(hydroxy)(1-methyl-1H-imidazol-5-yl)methyl)-2- by chiral HPLC (ChiralcelOD-H, EtOH) Methoxy-3-(3-(trifluoromethyl)phenyl)quinoline-4-carbonitrile gives 2 enantiomers. Example 2b: (The first enantiomer eluted from the chiral column) 1 HNMR(400MHz, CDCl 3 , A 1.1:1 mixture of rotamers, the minor rotamer peaks are marked with *)δ8.28(s,1H), 8.24*(s,1H),7.84-7.91(m,2H), 7.71 -7.84(m,6H),7.63-7.71(m,2H),7.43-7.50(m,2H),7.29-7.33(m,2H),7.21(s,2H),4.76(d,J=14.65Hz ,1H),4.59*(d,J=11.12Hz,1H),4.06*(s,6H),3.94(d,J=12.63Hz,1H),3.68-3.80(m,1H), 3.29(s, 3H), 3.27*(s,3H),3.22(s,1H),3.13-3.22*(m,1H),3.10*(s,1H),2.93-3.04(m,1H),2.58-2.71(m ,1H),2.23-2.57(m,5H),2.04(s,3H),2.03(s,3H),1.12-1.47(m,6H); MSm/e564.2[M+H] + , And Example 2c: (the second enantiomer eluted from the chiral column) 1 HNMR(400MHz, CDCl 3 , 1.1:1 mixture of rotamers, the minor rotamer peaks are marked with *)δ8.28(s,1H),8.24*(s,1H),7.88-7.90*(m,1H), 7.85-7.87(m,1H),7.71-7.83(m,6H),7.64-7.71(m,2H),7.42-7.50(m,2H),7.31-7.34(m,2H),7.22(s,2H) ), 4.77(d,J=13.14Hz,1H), 4.60*(d,J=14.15Hz,1H), 4.07(s,6H), 3.94*(d,J=14.15Hz,1H), 3.68-3.80 (m, 1H), 3.28(s, 3H), 3.27*(s, 3H), 3.13-3.23(m, 1H), 2.96-3.05*(m, 1H), 2.95(s, 1H), 2.84*( s,1H),2.58-2.70(m,1H),2.22-2.57(m,5H),2.05*(s,3H),2.03(s,3H),1.17-1.45(m,6H); MSm/e564 .2[M+H] +.

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products